prostate cancer

Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug

Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug

Bloomberg

Astellas forecasts big sales growth as prostate drug catches hold

Astellas forecasts big sales growth as prostate drug catches hold

Fierce Pharma

Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation

Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation

Yahoo/Minyanville

Medivation, Astellas Pharma provide update on Phase 3 PREVAIL

Medivation, Astellas Pharma provide update on Phase 3 PREVAIL

Yahoo/Fly on the Wall

Nymox Pharmaceutical (NYMX +3.2%) is set to close in the green today after the company provided a positive update on Phase 2 clinical trials for NX-1207

Nymox Pharmaceutical (NYMX +3.2%) is set to close in the green today after the company provided a positive update on Phase 2 clinical trials for NX-1207

Seeking Alpha

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players

Motley Fool

Medivation falls after analyst says Xtandi must overcome obstacles

Medivation falls after analyst says Xtandi must overcome obstacles

The Fly on the Wall

Johnson & Johnson's Pioneering Zytiga And Its Competitors

Johnson & Johnson's Pioneering Zytiga And Its Competitors

Seeking Alpha

Can Zytiga Build on a Historic 2012?

Can Zytiga Build on a Historic 2012?

Motley Fool

Progenics Pharmaceuticals Presents Updated Data From Phase 1 Study of PSMA ADC

Progenics Pharmaceuticals Presents Updated Data From Phase 1 Study of PSMA ADC

Pipeline Review